Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Modafinil on Lorlatinib PK in Healthy Volunteers
NCT03961997Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs), Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities and 1 more. Started Aug 2019; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03961997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961997.